$VBIV - 12-month price target for the shares is US$9.3!!!! Recent News! VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine! Plus, VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.